The machinery involved in cytotoxic T-cell activation requires three main characters: the
major histocompatibility complex class I (MHC I) bound to the peptide (p), the T-cell receptor …

The development of soluble tetrameric MHC/peptide complexes has opened the possibility
to directly identify and monitor antigen-specific CD8+ T cells in different clinical situations …

The supply of MHC class I-restricted peptides is primarily ensured by the degradation of
intracellular proteins via the ubiquitin-proteasome system. Depending on the target and the …

NY-ESO-1 is an attractive candidate tumor antigen for the development of immunotherapies
for a wide variety of cancers. It is expressed in multiple types of tumors, but its normal tissue …

During the course of developing a synthetic route for the cancer protein NY‐ESO‐1 using
native chemical ligation, a number of the required thioester polypeptide fragments were …

Many tumor antigenic determinants have been identified and included in cancer clinical
trials. Due to low T-cell frequencies even after vaccination, few T-cell responses can be …

Dose-response experiments are a mainstay of receptor biology studies and can reveal
valuable insights into receptor function. Such studies of receptors that bind cell surface …

Effective immune responses against intracellular pathogens and tumors frequently rely upon
CD8+ cytotoxic T lymphocytes (CTLs). In turn, CTL detection of foreign material from viruses …

UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2= CC
(= O) C= C [C@] 2 (C)[C@] 2 (F)[C@@ H] 1 [C@@ H] 1C [C@@ H](C)[C@@](C (= O) …

The present invention is related to the fields of molecular biology, virology, immunology and
medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP …